BillionToOne is a precision diagnostics company founded in 2016 and headquartered in Menlo Park, California. The firm is publicly traded on NASDAQ under the ticker BLLN and employs over 500 people. Its core technology is a proprietary single-molecule next-generation sequencing (smNGS) platform, which uses quantitative counting templates (QCTs) to detect disease signals at concentrations as low as 0.01% - a level of sensitivity that conventional methods miss.
The company's product portfolio spans prenatal care and oncology. UNITY Complete® is a non-invasive prenatal test (NIPT) that evaluates fetal risk for both recessive conditions and aneuploidy from a single maternal blood draw as early as nine weeks of gestation. In oncology, BillionToOne offers Northstar Select® for pan-cancer liquid biopsy therapy selection and Northstar Response® for real-time treatment monitoring.
BillionToOne's work sits at the intersection of molecular diagnostics, liquid biopsy, and non-invasive prenatal testing. The company states its mission is to make molecular diagnostics more accurate, efficient, and accessible for all patients.
